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E-mail address: tienh@bu.edu (T. Hsu).The von Hippel-Lindau tumor suppressor gene (VHL) is best known as an E3 ubiquitin ligase that
negatively regulates the hypoxia inducible factor (HIF). VHL mutations are the genetic defects
underlying several human diseases including polycythemia, familial VHL tumor syndrome and spo-
radic renal cell carcinoma. VHL mutations can lead to cell-autonomous phenotypes in the tumor
cells. However, non-tumor cell-autonomous functions of VHL have also been noted. VHL tumor-
derived cytokines can promote inﬂammation and induce mobilization of endothelial progenitor
cells. Up-regulation of HIF caused by VHL loss-of-function mutants, including heterozygotes, has
been shown to increase the activities of hematopoietic stem cells, endothelial cells and myeloid
cells. As such, systemic functions of VHL likely play important roles in the development of VHL
disease.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The von Hippel-Lindau tumor suppressor gene (VHL) encodes a
multifunctional protein, the mutations of which underlie the ge-
netic defect in the familial VHL disease. Germ line mutations in
VHL predispose the patients to several highly vascularized benign
and malignant tumors, including renal cell carcinoma of the
clear-cell type (ccRCC), hemangioblastoma (HB) and pheochromo-
cytoma (tumor in the adrenal glands). Less frequent VHL tumors
include those in pancreas (pancreatic cysts, serous cystadenoma
and pancreatic neuroendocrine tumors), inner ears (endolym-
phatic sac tumor) and testes (epididymal cystadenomas). In these
tumors, the remaining wild-type allele is inactivated through so-
matic mutation. Biallelic loss of VHL function has also been found
in a majority of the sporadic ccRCC [1–3]. The protein encoded
by the VHL gene is best known as the substrate-binding subunit
of an E3 ubiquitin ligase [4–8]. The best-known degradation target
of VHL-containing E3 ligase is the a-subunit of hypoxia-inducible
factor (HIF-a) in normal physiological conditions [9]. At normal
oxygen level, HIF-a is hydroxylated at the proline residues within
an oxygen-dependent degradation domain. The prolyl-hydroxyl-
ated HIF-a is recognized by VHL, leading to poly-ubiquitination
and degradation. The hydroxylation reaction is mediated by the
prolyl-hydroxylase domain proteins (PHDs) [10]. In hypoxicchemical Societies. Published by E
Medicine, Boston University
A 02118, United States. Fax:conditions, the prolyl-hydroxylases are inactive and HIF-a is stabi-
lized. HIF-a then dimerizes with the b-subunit (HIF-b) and translo-
cates to the nucleus where the dimer functions as a transcription
factor. Its best-known target genes encode proteins involved in
glycolysis (e.g., phosphoglycerate kinase), glucose transport
(Glut-1), angiogenesis [vascular endothelial growth factor (VEGF)]
and erythropoiesis (erythropoietin); that is, proteins that mediate
the cellular response and adaptation to hypoxic conditions [11].
In addition, CXC chemokine receptor 4 (CXCR4) and the ligand
stromal cell-derived factor (SDF)-1 were also identiﬁed as HIF tar-
gets [12,13], which indicates that HIF activation may contribute to
the metastatic potential of cancer cells. These functions support a
critical role of VHL in regulating tumor progression, especially in
hyper-vascularized tumors such as ccRCC and HB. However, accu-
mulated evidence has indicated that many HIF-independent activ-
ities of VHL also exist [14,15]. Some of these functions are
mediated through stabilizing VHL targets, contrary to its known
E3 ligase activity. Therefore, VHL is a multifunctional adaptor pro-
tein that, depending on the interacting partners, can promote pro-
tein degradation or serve as a chaperon. Some of these diverse
activities likely also contribute signiﬁcantly to the tumor suppres-
sor and other physiological functions.
These diverse functions also suggest that there may not be a
simple, uniﬁed pathophysiological mechanism that can explain
the etiology of VHL diseases. Although cell-autonomous mecha-
nisms in VHL mutant tumors might be explained by up-regulation
of cyclin D1 [16], increased Akt-mTOR signaling [17,18], elevated
FGF receptor signaling [19,20], disruption of cilia formation
[21–23], down-regulation of p53 [24], among others, it is also welllsevier B.V. All rights reserved.
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growth factors and cytokines, including erythropoietin (Epo),
VEGF, TGF-b, PDGFb, TNF-a, among many others [11]. Further-
more, in the last decade, it has become apparent that HIFs play a
central role in the hematopoietic system [25–28]. VHL mutations
and the resulting HIF up-regulation therefore can impact many
vasculo/hematopoietic lineages. Also interestingly, some of these
abnormalities can occur in partial VHL loss-of-function mutants
and in heterozygous mice and heterozygous immune cells from
VHL patients [20,29,30]. During development, the Drosophila VHL
gene also shows haploid insufﬁciency [31]. The haploid-insufﬁ-
cient function of VHL may be profoundly important in considering
the etiology of VHL disease since all VHL patients are, by deﬁnition,
VHL heterozygotes. Such understanding prompted the idea that a
non-cell autonomous and systemic consideration of the VHL func-
tion in the context of VHL disease may need to be evaluated. This
review examines the current knowledge in this regard. The role
of VEGF and PDGFb over-expression in VHL tumor angiogenesis
is well known and will not be discussed herein.2. VHL-associated polycythemia
A homozygous missense mutation in the VHL gene, ﬁrst
identiﬁed in the Chuvash region of Russia and called the Chuvash
mutation (R200W), was linked to a familial form of polycythemia
– overexpansion of erythrocytes [32]. Subsequently, a knockin
R200W transgenic mouse and a zebraﬁsh VHL null mutant also
exhibited polycythemia [33,34]. Erythropoiesis is regulated by
Epo, and polycythemia can be caused by hypersensitivity to Epo
(called primary polycythemia or polycythemia vera), or by over-
production of Epo (secondary polycythemia) [33,35,36]. Interest-
ingly, VHL-associated polycythemia has features of both primary
and secondary polycythemia [36]. Epo is normally produced by
interstitial ﬁbroblasts in the kidney [37,38] and by perisinusoidal
(Ito) cells in the liver [39]. HIF over-expression leads to up-regula-
tion of Epo, not only in the normal Epo-producing cells but also in
the VHLmutant tumor cells [40–43]. However, erythrocyte progen-
itors harboring the R200Wmutation are also more sensitive to Epo
[33,35,36]. The mechanism of this hypersensitivity has been dis-
covered only recently. The Epo receptor (EpoR) signals through
the JAK-STAT pathway: upon ligand binding, the receptor-associ-
ated tyrosine kinase JAK2 is phosphorylated and in turn phosphor-
ylates the transcription factor STAT5 [36,44]. In a negative
feedback loop, phosphorylated JAK2 (pJAK2) is targeted for prote-
asomal degradation by ubiquitination [44]. VHL was found to
mediate pJAK2 polyubiquitination, and in polycythemia-associated
VHL mutations, a failure to eliminate pJAK2, leading to prolonged
JAK-STAT signaling, was observed [35]. This phenotype could be
rescued both in vitro and in vivo by administration of the JAK2
inhibitor Tg101209, indicating that JAK2 inhibitors may prove use-
ful in the treatment of polycythemia. Surprisingly, VHL-mediated
pJAK ubiquitination did not require the formation of the well-char-
acterized ElonginB/C-Cul2-VHL E3 ligase complex [5]. Instead,
pJAK2 ubiquitination depended on the formation of a complex of
pJAK2, SOCS1 and VHL. The presence of primary polycythemic phe-
notype also indicates that VHL mutant erythrocyte progenitors
may be a contributing factor to the disease.3. The role of Epo in angiogenesis and tumorigenesis
Polycythemia has been considered an isolated branch of the
VHL syndrome, mainly because the Chuvash disease (R200W mu-
tant) patients do not exhibit increased incidences of tumors [45].
This notion may need to be reconsidered, however, since Epo has
been shown to have pleiotropic effects [46,47], including a rolein tumorigenesis. Epo signaling is not restricted to red blood cells.
Also, the Epo/EpoR system is known to induce proliferation, che-
motaxis, and angiogenesis, and inhibit apoptosis [46,48,49]. Epo
has been found to exert a strong cyto-protective effect in animal
models of brain, cardiac and renal ischemia (reviewed in [47]).
Epo signaling appears to inhibit apoptotic pathways triggered by
ischemia, but may in addition reduce hypoxic injury by promoting
angiogenesis. Epo administration to ischemic patients is therefore
currently subject to clinical trials. Epo and EpoR are also expressed
in various tumors including those of head-and-neck [50], breast,
colon, lung, prostate [51], ovary [51,52], uterine [52], kidney
[40,42,43] and cervix [53], as well as neuroblastoma, astrocytoma,
and other solid nervous system tumors [54], and numerous malig-
nant cell lines [55,56]. Epo added to cancer cell lines in vitro elic-
ited secretion of angiogenic growth factors and promoted
proliferation and chemotaxis of endothelial cells [54]. Neutralizing
anti-Epo monoclonal antibody and soluble EpoR antagonist in-
jected into ex vivo cultured tumor tissue blocked tumor growth
[52] and soluble EpoR antagonist injected into mice carrying can-
cer cell xenografts reduced angiogenesis and tumor cell survival
[55]. Furthermore, Epo pretreatment of some cancer cell lines ren-
dered them less sensitive to the cytotoxic effects of the chemother-
apy drug cisplatin [56]. Of note, polycythemic mice were shown to
be iron deﬁcient [57], most likely because the Epo-induced eryth-
ropoiesis led to an exhaustion of iron stores. Since iron is a neces-
sary co-factor of proline hydroxylases, it is tempting to speculate
that Epo-induced iron deﬁciency may be a mechanism by which
tumors mediate systemic HIF up-regulation.
Interestingly, although full-blown polycythemia is infrequent in
VHL disease, consistently elevated Epo is detected in a majority of
VHL patients [58]. In addition, certain heterozygous VHLmutations
can lead to polycythemia [59–61]. There is also an established
association between hemangioblastoma and polycythemia [62]. It
is therefore conceivable that elevated Epo level in VHL patients,
whether or not it manifests into polycythemia, may contribute to
progression of various VHL tumors.4. VHL and endothelial progenitor cells
Based on the observation that mononuclear cells isolated from
bone marrow or peripheral blood can give rise to endothelial colo-
nies, the existence of endothelial stem cells – called endothelial
progenitors cells (EP or EPCs) or, if detected in the peripheral blood,
circulating EPCs (CEP/CEPC) – has been postulated (reviewed in
[63,64]). Importantly, EPCs need to be distinguished from a subset
of monocytes that express endothelial markers such as VEGFR1,
VEGFR2, Tie2 and CD31. These monocytes are sometimes referred
to as circulating angiogenic cells (CACs). CACs contribute to
angiogenesis by releasing proangiogenic cytokines, but do not
differentiate into endothelial cells; instead they differentiate into
a subset of tumor promoting macrophages (discussed in Section
6) [63,65]. CACs and CEPCs are CD45 positive and negative,
respectively.
It has been proposed that CEPCs may contribute to tumor angi-
ogenesis, although this is still somewhat controversial (see for in-
stance [48,66]). Nevertheless, there is evidence that CEPCs are
relevant to VHL tumors. Patients with ccRCC were found to have
elevated levels of CEPCs [67]. In addition, high levels of VEGFR2-
positive cells in the peripheral blood were found to correlate with
a poor prognosis in ccRCC [68]. Interestingly, elevated CEPCs were
also detected in a case of sporadic ccRCC caused by somatic VHL
inactivation [69]. Therefore CEPC mobilization observed in VHL
tumors may result from both intrinsically higher motility of the
EPCs or from stimulation emanating from the VHL tumors. In
the latter case, VHL tumors can induce CEPC mobilization through
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can also induce the mobilization of VEGFR1+ CACs, at least in part
through VEGF [71].
5. VHL, HIF and the hematopoietic system
The role of HIF in the immune system has been extensively re-
viewed [25–28,72]. We will therefore summarize only some of the
most recent ﬁndings and highlight papers that directly address the
role of VHL.
In the last decade it has become evident that HIF, and in partic-
ular HIF-1a, regulates hematopoietic stem cells, and both innate
and adaptive immune cells [25–29,72]. In contrast, the role of
VHL in these cell lineages has been addressed only in a small num-
ber of studies. However, there is evidence that cells of the hemato-
poietic system are sensitive to even small changes in HIF-1a
expression levels. Hence, in many cases, opposite phenotypes are
observed in HIF-1a/ and VHL/ cells, and in some cases VHL
haploinsufﬁciency is observed, with VHL+/ cells displaying a phe-
notype that is intermediate to that observed in HIF-1a/ and
VHL/ cells [29,30]. This is consistent with a model that impli-
cates the importance of HIF-1a dosage: HIF-1a/ cells display
loss of function, VHL+/ cells intermediate gain-of-function due
to moderate HIF-1a up-regulation, and VHL/ cells hyper- or
malfunctioning due to high-level HIF-1a over-expression.
It is now recognized that lymphatic organs as well as sites of
inﬂammation are hypoxic [28,29]. Cells of the hematopoietic sys-
tem rely to a large extent on an anaerobic source of ATP: glycolysis
[73–75]. Since it is the master transcription factor of glycolysis re-
lated genes, HIF-1a plays a prominent role in many lineages of the
hematopoietic system [28,73–75], and defects in HIF-1a deﬁcient
immune cells can be in part explained by decreased ATP levels
[74]. Besides its role in regulating glycolysis, HIF-1a also regulates
apoptosis, cell proliferation and differentiation of the hematopoi-
etic lineages. For instance, it was recently shown that HIF-1a is
necessary for the maintenance of quiescence in long-term hemato-
poietic stem cells (LT-HSC) [29]. In an induced conditional HIF-1a
knockout (using Poly I:C induced Mx1-Cre), LT-HSCs showed in-
creased proliferation when experimentally challenged as well as
upon aging. The increased proliferation led to senescence, and ulti-
mately to an exhaustion of the LT-HSC pool. Consequently, HIF-
1a/ HSCs failed to reconstitute the bone marrow in serial trans-
plantations. In contrast, deletion of VHL in HSCs led to increased
quiescence and increased numbers of HSCs, in particular LT-HSCs.
However, these VHL mutant HSCs were not functional: they failed
to reconstitute the bone marrow in transplantation experiments
due to a combination of abnormal quiescence, homing defects
and enhanced apoptosis [29]. The observed defects in VHL/
HSCs were HIF-1a dependent and cell autonomous. Interestingly,
heterozygous VHL HSCs displayed an intermediate phenotype:
deletion of one VHL allele led to increased quiescence and in-
creased numbers of HSCs; however, in contrast to VHL/ HSCs,
VHL+/ HSCs were functional and reconstituted the bone marrow
of lethally irradiated mice even more efﬁciently than wild-type
HSCs. Hence, HIF-1a levels in HSCs are ﬁne-tuned to maintain a
balance between quiescence necessary for the maintenance of
the HSC pool, and proliferation necessary to replenish the hemato-
poietic system. The increased HSC activity conferred by VHL heter-
ozygosity may be a signiﬁcant contributing factor in the
progression of VHL disease, considering the hypervascularity asso-
ciated with the VHL tumors and the potential contribution from
inﬂammatory response (see below).
HIF-1a also plays an important role in lymphocytes. HIF-1a
deﬁciency leads to an increase in B1 B cells, and a concomitant
reduction in B2 B cells, the latter due to a lack of proliferation ofpro-B cells [76]. The role of VHL in B cell differentiation has not
been directly addressed, but epigenetic down-regulation of VHL
has been recently reported in diffuse large B cell lymphoma and
chronic lymphocytic leukemia [77–80].
The role of HIF-1a in T cells differentiation and activation is
somewhat controversial, although conﬂicting ﬁndings may be in
part explained by distinct roles of HIF-1a in different T cell sub-
sets and immature vs. mature T cells. Neumann and colleagues
reported attenuated T cell receptor (TCR) signaling in VHL/ T
cells [81]. This effect was HIF-1a-dependent, since it was not
observed in VHL/ HIF-1a/ T cells. Hence, HIF-a expression
appears to regulate TCR signaling negatively. Consistent with this,
deletion of VHL in the thymus led to increased apoptosis of T cells
at the double positive stage (a stage at which T cells are positively
selected for a functional TCR) [82], resulting in a decrease in
mature T cells. Furthermore, HIF-1a/ T cells were reported to
produce more inﬂammatory mediators – such as IFNc and TNFa
– than wild-type T cells when stimulated in vitro [83]. Also, mice
in which HIF-1a was deleted in T cells showed improved survival
of sepsis due to T cell activation [84]. In contrast to these ﬁnd-
ings, which indicate that HIF-1a negatively regulates T cell sur-
vival and activation, hypoxia induced HIF-1a was found to
inhibit activation induced cell death (AICD) in T cells [85]. How-
ever, this protective effect may be also explained by attenuated
TCR signaling, since AICD is TCR dependent. On the other hand,
it is difﬁcult to reconcile the anti-inﬂammatory effects of HIF-
1a discussed above with the recent ﬁnding that HIF-1a is essen-
tial for the induction of Th17 cells, a pro-inﬂammatory CD4 T cell
subset [86]. CD4 T cells can differentiate into either Th17 or Treg
T cells, depending on the cytokine environment [87]. RORct and
Foxp3 are key transcription factors in Th17 and Treg differentia-
tion, respectively, and Foxp3 also inhibits RORct [87]. Dang and
co-workers [86] showed that HIF-1a tips the balance towards
Th17 differentiation by inducing RORct. Consistent with these
ﬁndings, mice in which HIF-1a was conditionally deleted in CD4
T cells had reduced numbers of Th17 cells and were protected
from experimentally induced encephalitis (a model for autoim-
mune disease). Therefore, VHL+/ with moderate increase in
HIF-1a can potentially promote Th17-mediated inﬂammatory
response.
The role of HIF in the myeloid lineage was addressed using a
lysozyme M driven Cre, which led to efﬁcient deletion in both
macrophages and neutrophils [72,74]. In vivo experiments using
these conditional knockout mice show that both HIF-1a and
HIF-2a have essential roles in myeloid-mediated inﬂammation.
Myeloid HIF deletion protected mice from inﬂammation induced
by chemical irritation, experimentally induced autoimmune dis-
ease and LPS induced sepsis [72,74]. Conversely, mice with mye-
loid HIF deletion were impaired in controlling bacterial infections
[88]. These studies also showed that HIF-1a and HIF-2a have dis-
tinct, non-redundant roles in innate immunity. In myeloid cells,
HIF-1a is needed for ATP generation, granzyme synthesis and
iNOS/NO production, and, in neutrophils, protection from apopto-
sis, whereas HIF-2a mediates cytokine production and up-regu-
lates chemokine receptors involved in macrophage migration
[25,26,74,88]. Consistent with HIF over-expression upon VHL
deletion, HIF and VHL myeloid knockout resulted in opposite phe-
notypes both in vitro and in vivo [74]. VHL/ macrophages
produced more granzymes and iNOS/NO, and were more efﬁcient
than wild-type macrophages at lysing phagocytosed bacteria
in vitro. Furthermore, in a phorbol ester induced ear inﬂamma-
tion model, mice with myeloid VHL deletion displayed a signiﬁ-
cantly enhanced inﬂammatory response, although it was not
investigated whether this phenotype was solely due to HIF
over-expression [74].
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Based on the observation that HIF is essential for myeloid and
Th17-mediated inﬂammation, it is now thought that hypoxia is a
strong pro-inﬂammatory cue for immune cells [26–28,86,89].
Importantly, VHL haploinsufﬁciency, which is likely associated
with partial up-regulation of HIF, is observed both in HSCs and
neutrophils (see above) [29,30]. Also, in support of a link between
VHL and inﬂammation, it has recently been reported that pulmon-
ary hypertension, a complication of Chuvash polycythemia, is
caused by lung ﬁbrosis [90]. It is hence likely that the immune
system of VHL heterozygous individuals is skewed towards the
development of inﬂammatory responses. Such a pro-inﬂammatory
environment may contribute to tumorigenesis. Tumor inﬁltrating
macrophages, called tumor associated macrophages (TAMs), are
thought to promote tumor growth by releasing pro-angiogenic
and immunosuppressive cytokines. In support of this, a high
degree of TAM inﬁltration correlates with poor prognosis in human
cancers [65]. Nuclear HIF-2a was detected in TAMs of many hu-
man cancers [91], and conversely, myeloid HIF-2a deletion led to
a reduction in TAM recruitment, and concomitantly, slower tumor
growth [72]. It is tempting to speculate that VHL deletion (VHL/
or VHL+/) would lead conversely to faster tumor growth due to
more efﬁcient TAM recruitment and/or increased cytokine produc-
tion by TAMs. In addition, alterations in other immune cells, such
as Th17 T cells, could also promote tumorigenesis. It remains to
be elucidated if immune cells contribute to the formation of
tumors in VHL disease, and if so, which types of immune cells
are relevant in this process.
Besides a direct role in the immune cells, VHL knockouts in
mouse kidney epithelia have also been shown to induce an inﬂam-
matory response. A knockout strain speciﬁc for the podocyte in
kidney exhibited glomerulomegaly and occasional glomeruloscle-
rosis [92]. Interestingly, a Pepck-Cre driven (speciﬁc for proximal
tubules) VHL knockout could be induced to develop renal ﬁbrosis
after subtotal nephrectomy of one kidney and complete removal
of the other [93]. In addition, hypoxia and increased HIF-1a or
HIF-2a activities have been linked to kidney ﬁbrosis in mouse
[94,95]. VHL mutant ccRCC cells have been shown to over-produce
such inﬂammatory cytokines as TNFa [96] and TGF-b [97], and to
up-regulate NFkB [98,99], the latter can in turn induce cytokine
expression. The connection between VHL mutant cells and inﬂam-
mation is worthy of more in-depth investigation, since prolonged
inﬂammation can promote proliferation through the action of se-
creted cytokines, and importantly, can induce genetic changes in
pre-cancerous cells by induction of reactive oxygen species or by
oxidative inactivation of mismatch repair enzymes [100–103].
7. VHL, glucose metabolism and insulin secretion
b-Cells in the endocrine islets of the pancreas produce insulin
and store it in secretory vesicels [104]. Glucose stimulated insulin
secretion (GSIS) is essential for glucose homeostasis and is induced
by quantitative ATP generation after glucose uptake. A rise in the
ATP/ADP ratio induces the closure of ATP sensitive KATP channels,
leading to depolarization of the plasma membrane and Ca2+ inﬂux.
The Ca2+ inﬂux in turn stimulates the excocytosis of insulin. Hence,
insulin secretion is coupled to extracellular glucose concentration:
a rise in extracellular glucose concentration results in increased
intracellular ATP generation, and ultimately, in increased insulin
secretion. Since HIF-1a up-regulation is known to affect glucose
metabolism, the role of VHL in insulin-mediated glucose homeo-
stasis has attracted extensive interest. b-Cell (RIP2) or pan-
pancreas (Pdx2) speciﬁc Cre mice have been used to delete VHL in
b-cells [105–109]. Several studies reported that gross morphologyof the pancreas was unaffected by b-cells speciﬁc or pan-pancre-
atic VHL deletion [105–108], although two studies suggested an
age dependent decrease in b-cells [106,107]. In contrast, a recent
study reported development of precancerous lesions in pan-pan-
creatic VHL knockout mice, but not upon deletion of VHL in a- or
b-cells [109]. These differences are at least in part due to differ-
ences in the mouse strains used in the studies (mixed C57BL/6–
Sv129 vs C57BL/6, BALB/C or A/J) [110]. Interestingly, the b-cells
VHL knockout mice, but not the pan-pancreatic VHL knockout mice
displayed also dwarﬁsm [105,107,111]. Cantley et al. reported that
the dwarﬁsm was caused by RIP2-Cre activity in the hypothala-
mus, which led to reduced growth hormone (GH) production
[105], whereas Shen et al. did not observe a signiﬁcant down-reg-
ulation of GH [109]. It is possible that these differences are due to
the age at which the GH levels were assayed (3 months vs
6 months). More importantly, several studies showed that VHL
knockout in b-cells (pan-pancreatic or b-cell speciﬁc) led to im-
paired GSIS at high glucose concentrations (e.g., following glucose
injection), and consequently glucose intolerance (impaired clear-
ance of glucose from the blood), the hallmark of type-II diabetes
[105,106,108]. Impaired GSIS and glucose intolerance were found
to be HIF-1a dependent, since they were not observed in VHL
and HIF-1a double b-cell knockout mice [105,106]. In the cell, glu-
cose can be used for aerobic or anaerobic ATP generation. In the
aerobic pathway, glucose is processed to pyruvate, which is con-
verted to acetyl-CoA and is channeled into the tricarboxy acid
(TCA) cycle, generating electron donors for oxidative phosphoryla-
tion in mitochondria, with oxygen as the electron acceptor. In con-
trast, the less-efﬁcient glycolytic ATP generation involves the
processing of pyruvate to lactate. VHL deletion in b-cells led to
HIF-1a-dependent upregulation of pyruvate dehydrogenase kinase
1 (PDK1), which inhibits the conversion of pyruvate to acetyl-CoA,
preventing its entry into the TCA cycle, and Lactate dehydrogenase
A (LDHA), which generates lactate from pyruvate. Hence, as de-
scribed for other cell types, HIF-1a stabilization in b-cells induced
a metabolic switch from ATP generation through oxidative phos-
phorylation to ATP generation through glycolysis. Although these
studies disagreed on how glucose uptake and basal insulin secre-
tion were affected in VHL knockout cells, they demonstrated that
the lack of oxidative glucose metabolism was the likely cause of
the observed type-II diabetes phenotype. A link between VHL
mutation and diabetes has not been established clinically. None-
theless, the metabolic imbalance gleaned from the VHL functional
studies may help clarify some aspects of the etiology of type-II dia-
betes. These models also serve as an in vivo conﬁrmation of met-
abolic switch in the VHL mutant cells, which may be a relevant
contributor to the suspected metabolic-stress-induced inﬂamma-
tory response in cancer cells.
8. Hematopoietic stem cells, hemangioblastoma and VHL-
associated extramedullary hematopoiesis
HB is a highly vascularized tumor of the central nervous system
that affects the retina, cerebellum, brain stem and spinal cord
[112]. Although HB is a benign tumor, it is typically associated with
large peritumoral cysts, which cause morbidity and mortality by
exerting pressure on the surrounding neuronal tissue [112–114].
The exact etiology of HB is still unclear. HB consists of a vascular
and a stromal component [112]. Somatic VHL inactivation was de-
tected only in the stromal component [115–117]. Hence, although
they are sometimes described as such, HBs are not endothelial
tumors; rather, the overgrowth of endothelium is caused, at least
in part, by proangiogenic factors synthesized by the tumor. How-
ever, HB tumor cells not only express Epo, VEGF and angiopoietin,
but also the receptors of these cytokines (e.g., EpoR, Flk1/VEGFR2
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autocrine growth factors to promote both angiogenesis and tumor
growth. We have also shown that heterozygous VHL mice exhib-
ited elevated angiogenic activity in response to bFGF stimulation
due to increased FGF receptor accumulation in the endothelial cells
[20].
Most interestingly, there is evidence that HB tumor cells are de-
rived from developmentally arrested, hemangioblast-like stem
cells [119–122]. Hemangioblast is a structure that gives rise to
the ﬁrst endothelial and hematopoietic cells during embryogenesis
(e.g., the extraembryonic yolk sack associated blood island) [123],
and is thought to contain mesodermal stem cells that differentiate
into both endothelial and hematopoietic cells, or, as recent ﬁndings
suggest, sequentially into ﬁrst endothelial, then hematopoietic
stem cells, with a transient ‘‘hemogenic’’ endothelium [124,125].
Similar to the hemangioblasts, tumor cells in hemangioblastoma
express the early mesodermal marker Brachyury, as well as stem
cell markers such as Flk1/VEGFR2, the transcription factor stem
cell leukemia (scl) and CD133 [119,121]. Furthermore, tumor cells
isolated from hemangioblastoma give rise to both endothelial cells
and hematopoietic cells when cultured in vitro [121] and foci of
extramedullary hematopoiesis (EMH) are observed in advanced
hemangioblastoma [120,122]. Importantly, loss of heterozygosity
is observed in the foci of EMH [120], conﬁrming that they arise
from VHL/ cells. Since HB tumor cells can differentiate into
endothelial cells in vitro, it is possible that de novo vasculogenesis
contributes to the overgrowth of blood vessels observed in HB.
Vortmeyer and co-workers detected fetal hemoglobin in HB-asso-
ciated EMH foci, arguing that the VHL/ cells found in HB con-
tribute to primitive hematopoiesis [122]. The hematopoietic
progenitor characteristics of these HB cells imply that they may
originate from aberrantly mobilized HSCs.
However, HB has also been reported to express neuronal mark-
ers such as neuron-speciﬁc enolase [126–129], neural cell adhesion
molecule [129–131], and glial ﬁbrillary acidic protein (GFAP),
although the latter is controversial, with some studies suggesting
that GFAP+ cells might correspond to entrapped astrocytes
[96,129,132,133]. Autopsy revealed widespread small ‘tumorlets’,
which are thought to be hemangioblast precursors, in the roots of
spinal nerves and the cerebellum of VHL patients [134–136]. De-
tailed histological and immunhistochemical analysis of tumorlets
and HB suggests that HB progresses from slowly proliferating mes-
enchymal cells to highly proliferative epithelioid cells, the latter
displaying the clear cell morphology typical for VHL cancers
[122,134,136]. Since the topology of hemangioblastoma coincides
strikingly with the expression pattern of scl in the developing
CNS, it was suggested that hemangioblastoma might arise from
dormant stem cells of neurectodermal origin [119]. However, the
expression of hemangioblastic markers and the mesodermal mar-
ker Brachyury is difﬁcult to reconcile with a neurectodermal origin.
On the other hand, no Brachyury expressionwas detected in tumor-
lets, which are thought to be dormant precursors of HB [134]. Due
to its hybrid neuronal-mesodermal phenotype, the origin of HB tu-
mors remains unclear. Nonetheless, it may be worth exploring
whether primitive HSCs or hemangioblast stem cells are implicated
in HB. The CNS localization could be explained by homing defects of
HSCs involving endothelial cell adhesion molecules or chemoat-
tractant cytokines speciﬁcally expressed by the CNS vasculature.
In support of this hypothesis, homing defects were observed in
VHL/ HSCs [29]. Furthermore, EMH targeting the spleen is ob-
served in the R100W knockin polycythemic mouse [33,35], despite
normal bone marrow function. Interestingly, leukemic EMH has
been linked to the CXCR4-SDF-1 chemotactic system [137]. This is
particularly relevant since CXCR4 is a HIF responsive gene that
was shown to be up-regulated in VHL mutant cell lines [12], and
is known to be expressed in ccRCC and HB [13]. Furthermore,CXCR4 was down-regulated in HIF-1/ macrophages [72], indi-
cating that HIF dosage regulates CXCR4 expression not only in
cancer cells, but also in hematopoietic lineages. Since the CXCR4
chemotactic system is utilized in embryonic neuronal cell migra-
tion [138], it is possible that VHL mutant HPSCs may be aberrantly
mobilized and ectopically localized to the future HB loci.
9. Perspectives
It has become increasingly clear that tumor progression is a sys-
temic problem that involves, at the very least, the host immune
and angiogenic responses. This is particularly true with the VHL
disease. In the case of VHL patients, the host hematopoietic and
immune systems are not simply responders to the growth of tu-
mors but active contributors to the disease. This is suggested by
the increasing body of evidence that links VHL function to the
activity of HSCs. Heterozygous VHL HSCs and endothelial cells both
show increased activities, suggesting that they may contribute to
the hypervascular phenotype of the VHL tumors. Haploid-insufﬁ-
cient HSCs may also promote tumor growth through increased
inﬂammatory response or directly contributing multipotent cells
to the tumor loci. In addition, VHL mutant tumor cells can secret
a number of growth factors and cytokines that can also activate
the inﬂammatory and angiogenic components of the primary tu-
mors. We therefore argue that in designing new treatments for
the VHL disease, a systemic approach including targeting the
hematopoietic system and the inﬂammatory response should be
considered.
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